GLP-1 telehealth video after the FDA warning letters
FDA warning letters made compounded GLP-1 marketing a claim-language problem. The equivalence phrases to strip, plus a who-qualifies script that clears review.
The FDA has issued warning letters to telehealth firms and compounders over how compounded GLP-1 products get marketed. Read across them and the pattern is not really about the drug. It is about sentences. The product a compounding pharmacy ships and the product a marketing team describes had drifted apart, and the letters closed the gap by naming specific language.
That makes this vertical unusual. In most healthcare marketing, the creative brief comes first and compliance edits it afterward. Here the claim set has to be settled before anyone writes a hook, because almost every high-converting phrase in the category is one of the phrases under scrutiny.
The letters are about equivalence, not compounding
Two failure modes account for most of what got flagged.
The first is implied approval. Compounded drugs are not FDA-approved. The agency does not review a compounded product for safety, effectiveness, or manufacturing quality the way it reviews an approved drug. So any sentence that puts "FDA" and your product in the same breath is wrong at the level of fact, not tone. This includes the sideways version, where the ad says the pharmacy is FDA-registered and lets the viewer complete the inference themselves. Facility registration is not product approval, and a video that leans on the ambiguity is making the claim.
The second is equivalence to a brand. Describing a compounded product by reference to Wegovy or Zepbound imports the approved drug's trial data, its label, and its safety profile into a product that has none of them. "Same active ingredient" is the polite form of this and it is still an equivalence claim, because the audience does not hear a chemistry statement. They hear "this is that, for less."
Everything downstream follows from those two. Once you accept that the script is the regulated object, the production question gets simpler.
The phrases to strip before storyboarding
| Phrase in the draft | Why it fails | What replaces it |
|---|---|---|
| "FDA-approved semaglutide" | Compounded products are not FDA-approved | No approval language at all |
| "Generic Wegovy" / "generic Ozempic" | No approved generic exists; "generic" signals an approved equivalent | Name what it actually is |
| "Same active ingredient as Zepbound" | Equivalence claim in chemistry clothing | Describe your program, not the brand |
| "Clinically proven to deliver X percent loss" | Borrows the brand sponsor's trial evidence | Cite nothing you did not generate |
| "Our FDA-registered pharmacy" placed next to product claims | Invites the approval inference | Move it out of product context or cut it |
| "Lose 20 lbs your first month, guaranteed" | Outcome guarantee, unsubstantiable on its face | Remove |
| "Results typical for our patients" over a transformation clip | Testimonial framing that needs real substantiation | Remove or substantiate properly |
The FTC's health-products compliance guidance and its endorsement rules sit on top of all of this, and they bite hardest on weight-loss creative specifically. Before-and-after imagery is the most common trap. We wrote up the general version in the before-and-after rules for health and beauty ads, and everything there applies with the volume turned up. If you are generating any part of a testimonial rather than filming a real patient, read the FTC fake review rule and AI testimonials first, because a synthesized patient story is not a gray area.
The visual makes the claim too
This is the part teams miss when they move to generated video. Your script can be clean and your b-roll can still say "Wegovy." An injector pen with a familiar silhouette, a blue-and-white color story, a dose dial in close-up: those read as brand reference to the same viewer the FDA is worried about, and they read that way at a glance, before the voiceover lands.
So the strip list has a visual column. Prompt away from recognizable pen geometry, brand palettes, and packaging cues. Generate neutral clinical environments, hands, consultation rooms, and abstract dosing graphics instead. When you review the cut, run the claim list against the picture with the sound off. If the muted version implies something the script does not say, the script does not protect you.
A who-qualifies script that survives review
The highest-value asset in this category is not an offer video. It is a physician-led explainer that tells a viewer whether they are a candidate, in the clinician's own words, with no product claim in it at all. It converts because it answers the question people actually type, and it clears review because it is about eligibility rather than efficacy.
A 75-second structure that holds up:
- Identify the speaker, on screen and in voice. Name, credential, and the practice. Ten seconds. The credential is doing real work here; an anonymous voiceover in this category reads as an ad, a named prescriber reads as medicine.
- State what the video is and is not. "This is general information about who we can and cannot treat. It is not medical advice, and nothing here is a prescription." Eight seconds.
- Walk the intake, concretely. What you collect, what labs you require, what conditions require a different pathway, who you refer out. Thirty seconds. Specificity is the conversion mechanism.
- Name the disqualifiers out loud. The histories and conditions that mean this program is not appropriate. Fifteen seconds. Counterintuitively this is the segment that drives booked consults, because it signals a real clinical gate.
- Close on the next step, not the outcome. "If you want to know whether you qualify, the consultation is where that gets decided." Twelve seconds. No weight numbers, no timeline, no price-to-brand comparison.
Nothing in that script names a brand, promises a result, or touches approval status. It also does not need to. The eligibility question is the one with search volume behind it.
Producing it without a shoot
The practical problem is that prescribers have clinic hours and the script will change three times during review. Filming to a moving script is where budgets die.
The workable order is script first, generation last. Lock the language with your compliance reviewer as text, then build:
- Physician on camera. Record a consented reference clip once and drive subsequent scripts through the AI avatar generator, so a wording change is a re-render rather than a re-shoot. Disclose the synthetic delivery. In a category already under scrutiny for what it implies, an undisclosed digital presenter is an unforced error.
- Neutral clinical b-roll. Prompt for consultation rooms, lab draws, and hands, with no product, no packaging, and no pen. Empty rooms and materials-first framing carry the segment fine.
- Burned-in captions. Most of this is watched muted, and the disqualifier segment is the part that must land visually. Set them with the caption generator and check contrast on a phone, not a monitor.
- One timeline, many versions. The video editor works from a re-renderable EDL, so the round-three wording change is an edit rather than a rebuild. The 480p preview pass is free and carries a short per-user cooldown, which is enough to approve a cut before you spend credits on the final export. That export is charged once regardless of how many clips are on the timeline.
Versely bills in credits and the plan ladder is on pricing. What matters more for this vertical is the review loop, and the discipline that makes it work is covered in content approval workflows that don't stall: your reviewer signs off on the rendered file, not the script document, because tone and emphasis change between them.
FAQ
Can we say "compounded semaglutide" at all?
Naming what a product is differs from claiming what it is equal to. The risk is not the noun, it is the sentence around it. Where the letters landed was on approval language and brand equivalence, so the safe construction describes your clinical service and your pharmacy relationship without borrowing an approved drug's standing. Have your own regulatory counsel confirm the specific phrasing for your setup, because compounding pathways and state pharmacy rules vary.
Is a synthetic physician avatar acceptable here?
For a real, credentialed clinician appearing as themselves with recorded consent, it is a production method. Disclose it. What is not acceptable is a generated clinician who does not exist, or a stock presenter styled to read as a doctor. That is a claim about credentials made with pixels, and it is the same category of problem as the language the letters targeted. See AI video for healthcare clinics for how other practices handle the disclosure line.
What can we run as paid social?
Check the platform's healthcare advertising policy before you build a paid library, not after. Several platforms gate this category behind certification or prohibit certain product categories outright, and the requirements change. Build the organic and owned-site library first, because it is not subject to a policy review that can disappear your spend in a week.
How do we handle patient stories?
Real patients, real authorization that names video and social use, and honest context about what is typical. No generated composites, no reenactments presented as patients, no stitched testimonials from review text. The weight-loss category has the least tolerance of any for a fabricated result, and a generated transformation is the single fastest way to convert a marketing problem into an enforcement one.